Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Equity Income: 2015-2019

Historic Equity Income for Ligand Pharmaceuticals (LGND) over the last 5 years, with Dec 2019 value amounting to $2.9 million.

  • Ligand Pharmaceuticals' Equity Income fell 247.20% to -$25.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$39.9 million, marking a year-over-year decrease of 192.66%. This contributed to the annual value of $2.9 million for FY2019, which is 93.94% down from last year.
  • As of FY2019, Ligand Pharmaceuticals' Equity Income stood at $2.9 million, which was down 93.94% from $47.7 million recorded in FY2018.
  • Ligand Pharmaceuticals' Equity Income's 5-year high stood at $47.7 million during FY2018, with a 5-year trough of -$23.1 million in FY2016.
  • Its 3-year average for Equity Income is $17.2 million, with a median of $2.9 million in 2019.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Equity Income crashed by 349.78% in 2016, and later skyrocketed by 4,178.10% in 2018.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Equity Income stood at -$5.1 million in 2015, then tumbled by 349.78% to -$23.1 million in 2016, then spiked by 104.82% to $1.1 million in 2017, then skyrocketed by 4,178.10% to $47.7 million in 2018, then crashed by 93.94% to $2.9 million in 2019.